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Abstract (words: 249) 
Background 
Globally, type 2 diabetes (T2D) is a significant cause of avoidable mortality and morbidity. It 
is a major risk factor for cardiovascular disease (CVD). Evidence-based guidelines lower 
cardiovascular risk in diabetics. Adherence to clinical guidelines for the prevention of CVD 
in South African primary care public sector facilities is unknown.     
Aim 
This study determined adherence of Cape Town primary care clinicians to recommended 
clinical guidelines for the prevention of cardiovascular disease in T2D.  
Methods 
This 2013 cross-sectional study extracted data from 300 folders of known T2D patients 
sampled from three Community Health Centres (CHCs). Compliance with guidelines, and 
patient demographic factors were analysed.  
Results 
Most (71% or 194/273) hypertensive diabetics were appropriately managed with first-line- 
medication - an Angiotensin Converting Enzyme Inhibitor (ACEI). There was appropriate 
supporting documentation for only 39% not on first line therapy. A fifth (22%) with drug 
intolerance received the recommended alternative. Most were appropriately prescribed a 
statin (74%) and aspirin (69%). Other cardiovascular risk factors were poorly controlled: 
mean weights were in the obese range (BMI=31.3 [SD: 5.7]); the mean total cholesterol level 
was 5.5 (SD: 1.4); there was incomplete data for smoking (19% had no record) and 93% had 
no record of a family history of CVD. 
Conclusions 
Whilst pharmacological interventions for the prevention of CVD were moderately 
implemented, patient factors – such as obesity and smoking were poorly addressed. 
Improving documentation, adherence to recommended clinical guidelines and, health 
promotion to address modifiable risks are required to improve quality of care for T2D. 
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Study title  
Evaluating adherence to recommended clinical guidelines for the prevention of 
cardiovascular disease in patients with Type 2 diabetes mellitus at primary care level. 
Background and motivation   
Diabetes is a growing problem worldwide, including in Africa. Hall et al1 conducted a 
systematic review of papers published on diabetes in Sub-Saharan Africa from 1999 to 2011. 
They collected data on prevalence, complications, mortality and economic burden. The 
recorded population prevalence of Type 2 diabetes varied between countries, ranging from 
1% in rural parts of Uganda to 12% in urban Kenya. Patients with diabetes showed 5-year 
mortality rates ranging from 4%-57%. Type 2 diabetes (T2DM) accounted for more than 90% 
of diabetes in Sub-Saharan Africa1.  
T2DM can remain undetected for many years, and is often only diagnosed after incidental 
blood or urine glucose testing. Diabetes has traditionally been defined by elevated blood 
glucose, and the management of diabetes has focussed on glucose control. However, it is well 
known to be an independent risk factor for cardiovascular disease, and is an important cause 
of the decrease in life expectancy of people with diabetes. Non-glycaemic factors are 
critically important in the management of diabetes, especially with regard to reducing the 
associated cardiovascular risk and its effects. 2 Lowering this risk involves using multiple 
approaches. Lifestyle modifications such as exercise, smoking cessation, dietary intervention 
and weight regulation are still vital aspects of diabetes management and prevention of CVD.  
Motivation 
Primary care plays a key role in the prevention and management of cardiovascular disease in 
high risk patients such as diabetics. Most diabetics are managed at a primary care level in the 
public healthcare system, and the Metro District Health Services (MDHS) oversees primary 
healthcare services in the Cape Town area through a network of CHCs. Facilities serve 
mainly the uninsured, but also attend to patients on various medical aid schemes and funds. 
Patients are attended to by doctors and clinical nurse practitioners (CNPs). Patients attend 
monthly to receive their medication. The frequency of doctor/CNP visits will depend on how 
well the condition is controlled. Follow-up visits for chronic conditions like diabetes are 
usually 3-6 monthly. Generally, the CHCs have been perceived to deliver a substandard level 
of care for chronic illnesses, including T2DM, as was found in two studies. In 1992, Levitt et 
al3 audited 3 CHCs in Cape Town known to have high numbers of diabetic patients. They 
6 
 
looked at the level of control of blood sugar and blood pressure, and also the prevalence of 
complications related to diabetes. They found control to be poor- only 38% of patients had a 
normal blood pressure, and 49% had acceptable blood sugar control. There was also a high 
prevalence of complications, such as retinopathy, cataracts, peripheral neuropathy, peripheral 
vascular disease, amputations and kidney disease. They concluded that secondary prevention 
was not being adequately practiced as part of the management of diabetes. They suggested 
that the introduction of clinical guidelines would do much to improve health outcomes and 
reduce the prevalence of complications. The second study, conducted in 1999, Steyn et al4 
investigated diabetic and hypertensive control at a sample of CHCs in the Cape Town area. 
The data showed poor levels of control for these two diseases.  
Service audits have been introduced in MDHS services to address quality of care, including 
chronic diseases care. The first, conducted in 2008 at 15 CHCs within MDHS , followed 
accepted guidelines to assess clinical practice, the SEMDSA guidelines. They recommend 
that diabetics are reviewed in detail at least once annually, and this is known as the diabetic 
annual review.5  
SEMDSA provides nationally accepted clinical guidelines6 for the management of T2DM, 
which are distributed to clinical staff at CHCs within the MDHS. The diabetic annual review 
involves a number of tests and examinations which should be performed- some annually (e.g. 
visual acuity and dilated eye exam, foot exam, creatinine and lipid profile), and others more 
frequently (quarterly- HBA1C, or twice yearly if stable).  
The investigators demonstrated significant shortcomings in the level of care provided. This 
was reported to MDHS, and resulted in key changes being made to improve the care of 
diabetic patients. This inadequacy in the clinical management of diabetes is not limited to our 
setting. Brown et al7 conducted a study amongst family practitioners in Ontario, Canada. 
Similar parameters were measured, and compared to their recommended clinical guidelines. 
The results also showed a suboptimal level of clinical care for diabetics in that setting, with 
poor adherence to clinical guidelines by clinicians.  
 
Overview of the literature  
Epidemiology 
According to the World Health Organization (WHO), most deaths worldwide are caused by 
non-communicable diseases8. Burden of disease studies measure the health impact that 
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different diseases have on countries. The burden due to premature mortality is reflected as 
years of life lost (YLL), and the health burden due to morbidity (illness or injury) is reflected 
as years lived with disability (YLD). These two parameters are used to calculate disability-
adjusted life years (DALY) for specific causes. One can then determine the burden of 
different diseases, and then use the results to guide public health action.  
Green et al10 examined epidemiological data to find global prevalence estimates for Type 2 
Diabetes Mellitus (T2DM) for the year 2000 and then projections for 2030. It was calculated 
that the number of people with diabetes would double during that period. Sub-Saharan 
Africa, along with other developing regions, is expected to have the greatest increases in the 
number of people with diabetes.  
These findings indicate that diabetes will become an epidemic of global proportions, not only 
of developed countries. Risk factors for developing diabetes which linked to this are 
increasing obesity levels, inactivity, ageing populations and urbanization with its associated 
lifestyle and dietary changes.11   
Burden of disease for diabetes in South Africa     
Bradshaw et al9 investigated the burden of disease as a result of diabetes in South Africa in 
the year 2000.  The burden attributable to diabetes was found to be unacceptably high. The 
outcomes assessed were the DALYs for ischaemic heart disease (IHD), stroke, hypertensive 
disease and kidney disease. The estimated prevalence of diabetes in South Africans over the 
age of 30 years was found to be 5.5%, and increased with age.  The results showed diabetes 
to be responsible for 4.3% of all deaths in South Africa in 2000. Diabetes was associated with 
14% of IHD, 10% of stroke, 12% of hypertensive disease and 12% of kidney disease burden.  
In 1996 Levitt et al12 conducted a cross-sectional descriptive study in Mamre, a small town 
55km from central Cape Town. The aim was to assess the prevalence of T2DM in this peri-
urban, mainly ‘mixed race’, known as ‘coloured’ working-class community. The age-
standardised prevalence of T2DM in the 30-65 years’ age group was 10.8%. Since then South 
Africa has undergone major changes in many areas. In 2008 Erasmus et al13 performed a 
cross-sectional study in Bellville South, Cape Town in order to determine the prevalence of 
diabetes in an urban community. This is also a mainly coloured populated area. The study 
also targeted subjects over the age of 30 years. They found a high prevalence of T2DM 
(28%) in this area. This shows a substantial increase in the prevalence of diabetes in the 
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coloured population. These results indicate that diabetes is a significant public health 
problem. 
 Complications of T2DM - Cardiovascular risk  
There is ample evidence showing that T2DM is associated with a markedly increased CVD 
risk.14, 15 This has major public health repercussions, and will worsen with the projected 
increased incidence of diabetes. The Framingham Study,14 a prospective study over 20 years 
found the incidence of CVD in diabetic men to be twice that of nondiabetic men. In diabetic 
women the incidence of CVD was three times higher than in nondiabetic women. In a seven-
year Finnish study, after controlling for cardiovascular risk factors such as smoking, 
hypertension and lipid abnormalities, Haffner, et al 15 showed that diabetics had an equivalent 
risk for a myocardial infarction (MI) to that of non-diabetics with previous MI. They found 
that both groups were at increased risk for MI, and that the risk was similar for the two 
groups. They conclude from their findings that diabetics should be managed as if they have 
had prior CVD, and their cardiovascular risk factors should therefore be managed as 
aggressively as nondiabetics with known CVD. These findings were also supported by a 
study in Scotland, where subjects were followed over 25 years.16 They showed that diabetics 
have a lifetime cardiovascular mortality risk similar to that of nondiabetics with CVD.  
Haffner, et al17 performed a prospective cohort study among female nurses (who were free of 
known CVD) over a period of 20 years. They investigated the risk of MI in subjects and 
found that even during this pre-diabetic period (before being diagnosed with diabetes) there 
was a significantly higher risk of MI, as compared to the subjects who remained nondiabetic 
during the course of the study. The conclusions therefore are that both prediabetes and 
diabetes confer to the patient a higher CVD risk profile, and once there was clinical CVD, 
then the prognosis is even poorer. We should therefore do as much as we can to minimise this 
cardiovascular risk as much as possible.         
Guidelines    
The Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) 
guidelines6 are accepted nationally as evidence-based, and are applicable to the healthcare 
setting at a primary care level. These guidelines recommend the following actions for 
reducing CVD risk in Type 2 diabetics:                                                                                     
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 Blood Pressure Treatment 
An angiotensin-converting enzyme inhibitor (ACEI) should be the drug of choice as first-line 
therapy. Enalapril is the ACEI currently available in the MDHS. In case of ACEI- 
intolerance, an angiotensin receptor blocker (ARB) should be prescribed. Losartan is 
available- but its prescription needs to be initiated by a specialist physician.   
Lipid Treatment 
A statin should be prescribed for all Type 2 diabetics, regardless of baseline lipid levels: as 
primary prevention for those over 40 years with CVD risk factors, or secondary prevention if 
established CVD. Simvastatin is used in our setting, and can be initiated by a primary care 
doctor. 
Antiplatelet Agents  
(150mg/day) should be prescribed for all Type 2 diabetics: as primary prevention for those 
over 40 years or have CVD risk factors, or as secondary prevention for those with known 
CVD.  
 
The evidence for the above recommendations is outlined below. 
Blood Pressure 
According to the South African Hypertension Guidelines 2011,18 blood pressure targets are 
stricter for diabetics: systolic <130mmHg and diastolic <80mmHg, compared to targets of 
systolic <140mmHg and diastolic <90mmHg for a non-diabetic. Campbell et al19 investigated 
the management of diabetics with hypertension. They performed a systematic review of the 
literature on hypertension and diabetes. They found that hypertension commonly co-exists 
with diabetes- the pathogenesis of this is complex and multifactorial, and that this imparts a 
higher risk for CVD. Controlling the blood pressure has been shown in several trials to 
effectively reduce the associated cardiovascular morbidity and mortality. The HOPE study20 
showed that treating hypertensive diabetic subjects with the ACEI Ramipril was associated 
with a significant reduction in cardiovascular events. The ACEI effect was actually found to 
be independent of its effect on the blood pressure. The CAPPP (Captopril Prevention Project) 
trial used captopril to assess the effect on cardiovascular risk in diabetics with hypertension.21 
Compared with a diuretic and/or B-blocker regimen,captopril was shown to significantly 
reduce fatal and nonfatal cardiovascular events. Fatal cardiovascular events were reduced by 
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half. Studies using perindopril-based regimens22 also demonstrated cardiovascular protection 
for hypertensive diabetics.  
These studies therefore support the utilisation of ACEI-based regimens in the management of 
hypertension in the diabetic patient, in the drive to reduce cardiovascular risk.   
Lipids 
The Heart Protection Study23 compared simvastatin 40mg daily with placebo in randomly 
allocated diabetic subjects, and other individuals at high risk of vascular events. There was on 
average a 1.0mmol/L reduction of LDL-cholesterol levels in the simvastatin group, over the 
5-year study period. The subjects allocated to the simvastatin group experienced about a 25% 
reduction in a first major vascular event. Cardiovascular risk reduction occurred both in the 
presence and absence of established coronary artery disease. There were also significant 
reductions in subsequent vascular events. These beneficial effects were found, regardless of 
the subjects’ baseline lipid levels. The authors recommend that all diabetics who are at 
sufficiently high risk of vascular events should be considered for statin treatment, regardless 
of baseline lipid levels. The LIPID trial24 showed that pravastatin produced beneficial effects 
on cardiovascular risk, as the risk of a cardiovascular event was significantly reduced. The 
American Diabetes Association recommends that all diabetic patients should receive statin 
therapy: as secondary prevention for those with established CVD, and as primary prevention 
for those diabetics without known CVD, but over the age of 40 years and with one or more 
CVD risk factor.25  
Statins have therefore been shown to be instrumental in the drive to reduce cardiovascular 
risk in diabetic patients, and their use in these patients is recommended by authorities on the 
subject.  
Antiplatelet agents 
Acute ischaemic coronary events are mainly precipitated by thrombosis,26 and this is the 
mechanism of CVD in diabetics. Antiplatelet agents such as aspirin have been shown to be a 
key element of thrombosis prevention in individuals at high risk of thrombotic events. This 
was confirmed in meta-analyses performed by the Antithrombotic Trialists Collaboration,27 
where aspirin use was associated with a reduction in serious vascular events. The SEMDSA 
guidelines6 recommend that aspirin treatment should be provided for those diabetics with a 
history of prior CVD, or those with increased cardiovascular risk. This includes diabetics 
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over the age of 40, and those with additional risk factors, e.g. hypertension, smoking, 
dyslipidaemia and a family history of CVD.  
Adherence to guidelines 
Several studies have been performed to investigate adherence to clinical guidelines for the 
prevention of CVD in diabetics. The results varied widely, ranging from about 20% to about 
90%28,29,30 levels of adherence. The introduction of evidence-based clinical guidelines to 
change prescribing habits has been shown to reduce healthcare costs.31 Evidence-based 
clinical guidelines should therefore form the basis for the provision of good medical care. It is 
obvious that the prescribing habits of clinicians will directly impact on the cost of healthcare. 
However, the availability of guidelines does not necessarily lead to their application. In an 
environment with limited resources such as ours, cost should therefore factor into our 
prescribing habits. In practice, the obstacles are the dissemination of the guidelines, and then 
also the application by clinicians. What happens in our CHCs?  
Impact of the findings on practice  
Type 2 Diabetes is common and the incidence is increasing. With rising obesity rates 
worldwide, this trend is set to continue, and there is concern that it will reach epidemic 
proportions. Diabetes has major public health and economic impacts, and managing the 
disease and its complications is expensive.   
The level of adherence to recommended clinical guidelines impacts on quality and cost of 
care. So too can the extent to which they are made available at the facilities. With local 
studies showing poor control of chronic diseases and high prevalence of complications at 
primary care level, it will be useful to know what the level of adherence is to accepted 
guidelines for the prevention of morbidity and mortality from cardiovascular disease. A study 
that elucidates this would fill this gap and findings provided to clinicians and management, 
could inform improved practice.  
Study aims and objectives 
Aims 
The study aims to evaluate adherence to recommended clinical guidelines for the prevention 




A. Primary objectives 
1. To describe the demographic characteristics of type 2 diabetic patients managed at primary 
care level in the MDHS.                         
2. To determine the proportion of type 2 diabetics treated at primary care settings in Cape 
Town who are appropriately managed to reduce cardiovascular risk, specifically with regard 
to:                                                                         
a) Lipid treatment: are all Type 2 diabetics prescribed a statin, regardless of lipid levels.       
b) Blood pressure treatment: An angiotensin-converting enzyme inhibitor (ACEI) as first-line 
treatment for diabetics with raised blood pressure.                                         
c) Antithrombotic treatment: Low dose Aspirin (75-150mg daily)- as secondary prevention in 
all Type 2 diabetics with a history of CVD, or as primary prevention in those diabetics at 
higher risk, such as those over the age of 40 years, or those with additional CVD risk factors, 
e.g. hypertension, smoking, dyslipidaemia and a family history of CVD.        
3. To compare CHCs regarding level of adherence to recommended clinical guidelines, and 
to assess factors associated with good adherence to guidelines. 
B. Secondary objectives  
To make recommendations regarding the implementation of clinical guidelines at Primary 
Care level to reduce cardiovascular risk in Type 2 diabetics based on the results of the study.  
Study design, methodology, sampling and data analysis  
 
Definitions: 
Diabetic                  
A person who has diabetes, as classified by a PHC clinician.          
Hypertension                        
Blood pressure: systolic <130mmHg and diastolic <80mmHg.                        
High risk             
The patient has risk factors for CVD, e.g. hypertension, dyslipidaemia, smoking, obesity and 
a family history of IHD                   
Lipid treatment           
The patient is (at the time of the study) receiving Simvastatin, a statin drug, at a dosage of at 
least 10mg daily.              
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Antithrombotic treatment           
The patient is (at the time of the study) receiving Aspirin, an antiplatelet agent, at a dosage of 
75-150mg daily.         
Study design                           
The study design to be used is an observational cross-sectional study, which will review 
patient records, using patient medical records. The study will use existing data obtained from 
patient medical records.  
Sampling 
Source population:                        
Type 2 Diabetics attending 3 different CHCs in Cape Town for their chronic diabetic care. 
The 3 CHCs which will be used for the study are Hanover Park, Mitchells Plain and Retreat. 
These CHCs are known to have a heavy caseload of type 2 diabetic patients attending on a 
regular basis. However, as there are no registers at CHCs for chronic patients, there are no 
accurate figures available for the number of diabetics attending the CHCs.      
Sampling frame            
Attendees of the 3 CHCs who have previously been diagnosed with Type 2 diabetes, with at 
least 3 visits in the previous year.                
Inclusion criteria             
Age 40 years or older, being a documented attendee (a “club” patient), with at least 3 visits 
during the previous year for diabetes, and having received treatment for this condition at each 
visit.  
Methods    
Data collection                                                       
The data collection will be performed by the researcher. Permission to conduct research will 
be obtained from the facility Manager of each CHC. All patient records are filed and stored in 
the Records Department of each facility. Folders are filed according to their folder numbers.  
Folders of diabetics are not filed separately, but are marked with a sticker to distinguish them 
from other folders. Folders of diabetic patients will be retrieved and selected randomly (every 
second folder), and then filtered according to the inclusion criteria. The folders which fulfil 




Parameters              
Gender (male/female)            
Age                       
Known diabetic: yes/no                       
Time since diagnosis of diabetes (years)                            
3 Attendance visits past year for diabetes: yes/no                                
cardiovascular risk factors recorded, e.g. HTN, smoking, family history of IHD, 
dyslipidaemia Known/unknown IHD                  
ACEI: yes/no                          
ASA: yes/no                        
Statin: yes/no              
For each drug if “no”, then is there a documented contra-indication or history of drug 
intolerance.              
Sample size calculation                                                                                                                                                                                                                      
The sample size (n) is calculated according to the following formula:     
n = p(1-p)z2           
 d2                                                           
p= anticipated population proportion (50%) of good adherence to clinical guidelines.    
d= level of precision (10%)                            
z-score= 1.96 
n = 96 
Therefore 96 folders will be randomly sampled from each CHC.                              
                                                                                                                                                                                                                                                  
Data analysis                            
Descriptive statistics will be provided for all variables. All data will be entered onto an Excel 
spreadsheet and analysed. Categorical data will be presented as frequencies and percentages 
in tables. The chi-squared test will be used to test the difference between observed and 




Timeline and budget  
The anticipated timeline consists of the following phases:                                            
1. Submission to ethics committee for approval: end of February 2013        
2. Data collection: March- April 2013                                 
3. Data analysis: May 2013                                          
4. Completion and submission of research study: June2013.                                     
The fieldwork for the study will be done by the investigator once ethics approval is obtained. 
There is no budget allocation. Any costs incurred will be borne by the researcher.                                    
Ethical considerations and reporting of results                    
Ethical approval will be sought from the UCT Research Ethics Committee. Permission to 
conduct the study will be obtained from the MDHS and the facility managers at the relevant 
CHCs. There is no conflict of interest.            
Non-maleficence                        
Data will be sourced from patient medical records, so patients will not be exposed to any risk. 
Beneficence                                  
The study aims to promote the well-being of patients by investigating whether evidence-
based guidelines are being adhered to. Benefits of the research study will include making 
recommendations toward the improvement of healthcare at a primary care level.                                                                                              
Respect for Autonomy                               
All data will be collected from patient records. This information will be captured, analysed 
and then reported on without using any patient-identifying characteristics or personal 
information. This will ensure that patient confidentiality will be maintained.      
Justice               
In our setting, we struggle with scarce health resources. The study will promote cost-
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Table 2. Demographic characteristics 
FACTOR CASES (%) 
1. SEX  
Male  
Female  






Table 3. Prevalence of Cardiovascular risk factors  




Family History of CVD  




Table 4. Patients not on recommended drug compared to documented drug intolerance 
DRUG Drug prescribed  
n (%) 
Drug not 
prescribed            
n (%) 






Statin     
Aspirin     
ACEI     
 
Table 5. Use of drugs by gender and diabetes duration  
MEDICATION GENDER  DIABETES 
DURATION 
 
 Male Female <8 years >8 years 
Statin     
Aspirin     
ACEI     
 
Table 6. Comparison of 3 CHCs 
PARAMETER HPCHC MPCHC RCHC 
Sample size    
Demographic     
1. Age    
Prescribing habits    
1. ACEI/ARB    
2. ASA (if risk 
factor) 
   
3. Statin    
Risk factors     
1. IHD    
2. HTN    
3. smoking    
4. Obesity    




3. Literature Review 
 
Literature search strategy 
The literature search was performed in 2013. The following search engines were used to find 
relevant journal articles: Google Scholar, PubMed and Science Direct. WHO reports were 
also accessed. The search terms used were: diabetes, cardiovascular disease, adherence to 
guidelines, diabetes and statin, diabetes and angiotensin converting enzyme inhibitor, 
diabetes and aspirin 
Burden of disease 
According to the Global status report on non-communicable diseases 2010, published by the 
WHO, most deaths worldwide are caused by non-communicable diseases (NCDs). Almost 
two thirds of global mortality occurring in 2008 were due to NCDs, mainly comprising 
cardiovascular diseases (CVDs), cancers, diabetes and chronic respiratory diseases. Of 
particular concern is that it is not only the developed countries which are affected, but that the 
burden of CVD is already far advanced in poorer countries. The poorer countries will 
experience a “double burden from communicable diseases, as well as a rising incidence of 
non-communicable diseases such as diabetes and heart disease. It will be critical for policy 
makers to consider interventions to reduce the risk for CVD, and the report notes that the 
appropriate management of diabetes is an important factor in the reducing risk for CVD. 
There is evidence to show that Type 2 diabetes (T2DM) is a growing problem worldwide. 
Wild et al2 examined epidemiological data to find global prevalence estimates for T2DM for 
the year 2000 and modelled projections for 2030. They predict that the number of people with 
diabetes would double. Sub-Saharan Africa, along with other developing regions, is expected 
to have the greatest increases in the number of people with diabetes. These findings indicate 
that diabetes will become an epidemic of global proportions, in both developed and 
developing countries.  
The magnitude of the problem that Africa faces is significant, with studies showing that the 
prevalence of T2DM has increased considerably in Sub-Saharan Africa. This was highlighted 
in a systematic review looking at papers published on diabetes in Sub-Saharan Africa 
between 1999 and 2011, that investigated the prevalence, complications, mortality and 
economic burden of T2DM.3 T2DM accounted for more than 90% of diabetes in Sub-Saharan 
Africa, 3 and the population prevalence of T2DM varied between countries, ranging from 1% 
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in rural parts of Uganda to 12% in urban Kenya. Studies investigating mortality from diabetes 
in Sub-Saharan Africa found high rates, with 5-year mortality rates ranging from 4%-57%.3  
Bradshaw et al4 investigated the burden of disease as a result of diabetes in South Africa in 
the year 2000. The estimated prevalence of diabetes in South Africans over the age of 30 
years was 5.5%, and increased with age. In 2000, disease burdens attributable to diabetes 
were unacceptably high, with diabetes responsible for 4.3% of all deaths in South Africa. 
Diabetes was associated with 14% of IHD, 10% of stroke, 12% of hypertensive disease and 
12% of kidney disease burden.  
Studies conducted in the Western Cape confirm that T2DM is locally increasing in 
magnitude. A 1996 cross-sectional descriptive study in Mamre, a small working-class peri-
urban settlement 55km from central Cape Town found the age-standardised prevalence of 
T2DM in the 30-65 years’ age group to be 10.8%.5 A later 2008 cross-sectional community-
based study working-class urban Bellville South, Cape Town, found a high prevalence of 
T2DM (285) amongst adults over the age of 30 years. 6 This suggests a substantial increase in 
the prevalence of diabetes in a mixed-race working-class urban population, and indicate that 
diabetes is a growing important local public health problem. 
Risk Factors for Type 2 diabetes 
Risk factors for developing diabetes are increasing obesity levels, inactivity, ageing 
populations and urbanization with its associated lifestyle and dietary changes. 7 T2DM can 
remain undetected for many years, and is often only diagnosed after incidental blood or urine 
glucose testing. It has traditionally been defined by elevated blood glucose, and the 
management of diabetes in clinical settings is focussed on glucose control.8  
T2DM is well known to be an independent risk factor for cardiovascular disease, and is an 
important cause of the decrease in life expectancy of affected people. Studies show that non-
glycaemic factors are critically important in its management, and impact on associated 
cardiovascular risk and its effects. Lowering this risk involves using multiple approaches. 
Lifestyle modifications such as exercise, smoking cessation, dietary intervention and weight 
regulation are still vital aspects of diabetes management and prevention of CVD.8   
Diabetes and Cardiovascular Risk  
There is ample evidence showing that Type 2 diabetes is associated with a markedly 
increased CVD risk.9,10 This has major public health repercussions, which will worsen with 
the projected increased incidence of diabetes. Fox et al9 used subjects from the Framingham 
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Heart Study from a 50-year time period, and found that the proportion of CVD attributable to 
diabetes had increased over this time. They also found that, compared to other cardiovascular 
risk factors such as hypertension, smoking, hypercholesterolaemia and obesity, only diabetes 
showed an increase in the population attributable risk for CVD.  In a five-year Danish study, 
Schramm et al 10 showed that diabetics had an increased risk for a myocardial infarction (MI), 
similar to that of non-diabetics with previous MI. They concluded that diabetics should be 
managed as if they have had prior CVD, and their cardiovascular risk factors should therefore 
be managed as aggressively as for nondiabetics with known CVD. These findings are 
supported by a Scottish study, where subjects were followed over 25 years, which showed 
that diabetics have a lifetime cardiovascular mortality risk similar to that of nondiabetics with 
CVD.11  
A further prospective cohort study conducted among female nurses (who were free of known 
CVD) over a period of 20 years found that the risk of MI in subjects during a pre-diabetic 
period conferred a significantly higher risk of MI, as compared to the subjects who remained 
nondiabetic during the course of the study.12  
The evidence points to both prediabetes and diabetes conferring a higher CVD risk profile, 
and the prognosis is even poorer once there is clinical CVD. Clinical care for diabetics should 
be directed at minimising this cardiovascular risk as much as possible, thus improving their 
chances of survival as well as their quality of life.      
Guidelines for managing diabetes       
Non-communicable diseases are reported to be increasing globally, and of major concern is 
that the number of diabetics is projected to double between 2000 and 2030.2 Diabetes brings 
with it an elevated risk for cardiovascular disease. The Society for Endocrinology, 
Metabolism and Diabetes of South Africa (SEMDSA) guidelines13 developed guidelines to 
assist clinicians to better manage diabetes and prevent its complications. The guidelines are 
accepted nationally as evidence-based, and are applicable to the healthcare setting at a 
primary care level. These guidelines outline goals for the management of diabetes, and 
include factors like glycaemic control, lifestyle related risk factors and therapy for reducing 
cardiovascular risk and preventing cardiovascular events.  
The guidelines recommend the following actions for reducing cardiovascular risk in Type 2 
diabetics, and are outlined below, together with the evidence that they are based on.                                      
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Blood Pressure Treatment 
The SEMDSA recommendation for blood pressure (BP) target in most patients with T2DM is 
≤ 140/80 mmHg and ≥ 120/70 mmHg.13 For diabetics with hypertension, an angiotensin-
converting enzyme inhibitor (ACEI) should be the drug of choice as first-line therapy. 
Enalapril is the ACEI currently available in primary care services operated by MDHS. In 
cases of ACEI- intolerance, an angiotensin receptor blocker (ARB), Losartan, is available for 
prescription. Controlling the blood pressure has been shown in several trials to effectively 
reduce the associated cardiovascular morbidity and mortality. The HOPE study14 showed that 
treating hypertensive diabetic subjects with the ACEI Ramipril was associated with a 
significant reduction in cardiovascular events. The ACEI effect was actually found to be 
independent of its effect on the blood pressure. The CAPPP (Captopril Prevention Project) 
trial used captopril to assess the effect on cardiovascular risk in diabetics with hypertension.15
Compared with a diuretic and/or B-blocker regimen, captopril was shown to significantly 
reduce fatal and nonfatal cardiovascular events. Fatal cardiovascular events were reduced by 
half. Studies using perindopril-based regimens16 also demonstrated cardiovascular protection 
for hypertensive diabetics.  
These studies therefore support the utilisation of ACEI-based regimens in the management of 
hypertension in the diabetic patient, in the drive to reduce cardiovascular risk.  
Statin Treatment 
A statin should be prescribed for all Type 2 diabetics, regardless of baseline lipid levels: as 
primary prevention for those over 40 years with CVD risk factors, or secondary prevention if 
established CVD. Simvastatin is used in our setting, and can be initiated by a primary care 
doctor.  
The evidence for local regimens comes from the Heart Protection Study17 which compared 
simvastatin 40mg daily with placebo in randomly allocated diabetic subjects, and other 
individuals at high risk of vascular events. There was on average a 1.0mmol/L reduction of 
LDL-cholesterol levels in the simvastatin group, over the 5-year study period. The subjects 
allocated to the simvastatin group experienced about a 25% reduction in a first major vascular 
event. Cardiovascular risk reduction occurred both in the presence and absence of established 
coronary artery disease. There were also significant reductions in subsequent vascular events. 
These beneficial effects were found, regardless of the subjects’ baseline lipid levels. The 
authors recommend that all diabetics who are at sufficiently high risk of vascular events 
should be considered for statin treatment, regardless of baseline lipid levels. The LIPID trial18 
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showed that pravastatin produced beneficial effects on cardiovascular risk, as the risk of a 
cardiovascular event was significantly reduced. The American Diabetes Association 
recommends that all diabetic patients should receive statin therapy: as secondary prevention 
for those with established CVD, and as primary prevention for those diabetics without known 
CVD, but over the age of 40 years and with one or more CVD risk factor. 19  
Statins have therefore been shown to be instrumental in the drive to reduce cardiovascular 
risk in diabetic patients, and their use in these patients is recommended by authorities on the 
subject.                            
Antiplatelet Agents  
Aspirin (150mg/day) should be prescribed for all Type 2 diabetics: as primary prevention for 
those over 40 years or have CVD risk factors, or as secondary prevention for those with 
known CVD. The rationale for this is that acute ischaemic coronary events are mainly 
precipitated by thrombosis, 20 and this is the mechanism of CVD in diabetics. Antiplatelet 
agents such as aspirin have been shown to be a key element of thrombosis prevention in 
individuals at high risk of thrombotic events. This was confirmed in meta-analyses performed 
by the Antithrombotic Trialists Collaboration, 21 where aspirin use was associated with a 
reduction in serious vascular events.  
The SEMDSA guidelines13 recommend that aspirin treatment should be provided for those 
diabetics with a history of prior CVD, or those with increased cardiovascular risk. This 
includes diabetics over the age of 40, and those with additional risk factors, e.g. hypertension, 
smoking, dyslipidaemia and a family history of CVD.  
Setting 
Primary care plays a key role in the prevention and management of cardiovascular disease in 
high risk patients such as diabetics. Most diabetics are managed at a primary care level in the 
public healthcare system, and the Metro District Health Services (MDHS) oversees primary 
healthcare services in the Cape Town area through a network of CHCs. They serve mainly 
the uninsured, but also attend to patients on various medical aid schemes and funds. Patients 
are attended to by doctors and clinical nurse practitioners (CNPs), and attend monthly to 
receive their medication. The frequency of doctor/CNP visits will depend on how well the 
condition is controlled. Follow-up visits for chronic conditions like diabetes are usually 3-6 
monthly. Diabetics who are poorly controlled are referred to specialist clinics at district or 
tertiary level hospitals.         
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Generally, the CHCs have been perceived to deliver a substandard level of care for chronic 
illnesses.  
A 1999 study that reviewed diabetic and hypertensive control at primary care services in 
Cape Town22   showed that, despite the prior dissemination of disease management guidelines 
at CHCs, there was still ongoing poor control of chronic diseases at primary care level. The 
study revealed suboptimal levels of hypertension and diabetes control. Two thirds of patients 
had uncontrolled blood pressure and more than half of diabetics had raised glucose levels. 
There was poor control of risk factors, with most patients having hypercholesterolaemia and 
high levels of smoking. Record keeping was also poor, with documentation of prescribing 
decisions frequently absent.  
A study performed almost ten years later,23 looking at the management of hypertension at 
CHCs in Cape Town, showed that deficiencies in the quality of care of chronic conditions at 
primary care level persisted. Poor adherence to clinical guidelines by clinicians was identified 
as one of the factors leading to poor blood pressure (BP) control.  
Reviews of chronic disease control has been incorporated into regular audits as part of 
clinical governance functions driven by family physicians in Cape Town.24,25 A 2008 audit, 
conducted at 15 CHCs within the Metro District Health Services (MDHS) addressed quality 
of care. 24   It included T2DM and reviewed the compliance of diabetic management with 
SEMDSA guidelines. These nationally accepted guidelines13 for the management of T2DM 
are distributed to clinical staff at CHCs within the MDHS, and recommends an annual review 
of tests and examinations such as visual acuity and dilated eye exam, foot exam, creatinine 
and lipid profile. Others should be performed more frequently (quarterly- HBA1C, or twice 
yearly if stable). Important shortcomings were identified in areas such as clinical 
management, organization and continuity of care.  
This inadequacy in the clinical management of diabetes is not limited to our setting. A study 
amongst family practitioners in Ontario, Canada, that compared family physicians’ 
performance in managing T2DM to their recommended clinical guidelines found suboptimal 
levels of clinical care for diabetics with poor adherence to clinical guidelines.25 
A Cape Town clinical audit, published in 2012, investigated whether previous audits 
(performed in 2005, 2007, 2008 and 2009) resulted in statistically significant improvements 
in diabetes management at CHCs.26 The study findings revealed an improved performance in 
most clinical processes in diabetes management. The application of clinical audits was found 
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to have resulted in quality improvement in the management of diabetes in these resource-
limited settings. 
Adherence to guidelines  
Several studies have been performed to investigate adherence to clinical guidelines for the 
prevention of CVD in diabetics. 27-29 The availability of guidelines does not necessarily lead 
to their application, and levels of adherence vary widely, ranging from about 20% in an 
Italian study, 27 to about 90% in a Scottish study.28    
A Canadian study investigated management of cardiovascular risk factors and levels of 
adherence to Canadian Diabetes Association clinical guidelines for diabetics attending 
primary care centres.29 The study found that a significant number of patients were not 
managed to Canadian guideline standards. About half had sub-optimal glycaemic control, and 
half did not achieve the target blood pressure. Many patients were also not receiving 
appropriate medical therapy to lower cardiovascular risk.  
The introduction of evidence-based clinical guidelines to change prescribing habits has been 
shown to reduce healthcare costs. 30 Evidence-based clinical guidelines, however, should 
form the basis for the provision of good medical care, and prescribing habits of clinicians 
directly impact on the cost of healthcare. In an environment with limited resources such as in 
South Africa, cost should be factored into prescribing habits, to limit morbidity and mortality 
due to cardio-vascular complications of poorly controlled diabetes.  
It is not known what the adherence to guidelines for the prevention and management of these 
diabetic complications at primary care level are. The study informed by this review is 
designed to ascertain this.  
Motivation for this study 
Many of the cardiovascular complications of T2DM are preventable. In view of the 
increasing magnitude of the T2DM burden, and the morbidity, mortality it causes, and the 
cost and demand for care arising from complications, it is important to ascertain whether 
proven preventive measures are being implemented.  A study to determine the 
implementation of guidelines to manage cardiovascular risk factors at primary care level in 




The level of adherence to recommended clinical guidelines impacts on quality and cost of 
care. So too can the extent to which they are made available at the facilities. Feedback can be 
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Dear Editor, 
Attached please find a manuscript reporting on recent research conducted in primary care 
facilities. The article is titled: “Evaluating adherence to recommended clinical guidelines for 
the prevention of cardiovascular disease in patients with Type 2 diabetes mellitus at primary 
care level.”  
From the literature this is an under-researched but important issue.  It is hoped that the results 
of this study will help clinicians to see the importance of controlling cardiovascular risk 
factors, keeping good documentation and the value of evidence based clinical guidelines, all 
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Abstract (word: 249) 
Background 
Globally, type 2 diabetes (T2D) is a significant cause of avoidable mortality and morbidity. It 
is a major risk factor for cardiovascular disease (CVD). Evidence-based guidelines lower 
cardiovascular risk in diabetics. Adherence to clinical guidelines for the prevention of CVD 
in South African primary care public sector facilities is unknown.     
Aim 
This study determined adherence of Cape Town primary care clinicians to recommended 
clinical guidelines for the prevention of cardiovascular disease in T2D.  
Methods 
This 2013 cross-sectional study extracted data from 300 folders of known T2D patients 
sampled from three Community Health Centres (CHCs). Compliance with guidelines, and 
patient demographic factors were analysed.  
Results 
Most (71% or 194/273)  hypertensive diabetics were appropriately managed with first-line- 
medication - an Angiotensin Converting Enzyme Inhibitor (ACEI). There was appropriate 
supporting documentation for only 39% not on first line therapy. A fifth (22%) with drug 
intolerance received the recommended alternative. Most were appropriately prescribed a 
statin (74%) and aspirin (69%). Other cardiovascular risk factors were poorly controlled: 
mean weights were in the obese range (BMI=31.3 [SD: 5.7]); the mean total cholesterol level 
was 5.5 (SD: 1.4); there was incomplete data for smoking (19% had no record) and 93% had 
no record of a family history of CVD. 
Conclusions 
Whilst pharmacological interventions for the prevention of CVD were moderately 
implemented, patient factors – such as obesity and smoking were poorly addressed. 
Improving documentation, adherence to recommended clinical guidelines and, health 
promotion to address modifiable risks are required to improve quality of care for T2D. 
 
Keywords: diabetes, cardiovascular risk, adherence, guidelines, Angiotensin Converting 












According to the World Health Organization (WHO), the biggest killers globally are non-communicable 
diseases, with more than half of all deaths linked to cardiovascular disease CVD).1 Cardiovascular disease, 
important in the developed world, is a growing burden in poorer countries. In addition to the high burden of 
infectious disease epidemics and trauma, chronic diseases are increasingly a concern to health services and 
clinicians in developing countries.  
A systematic review focussing on articles on diabetes in Sub-Saharan Africa published between 1999 and 2011, 
found that diabetes exerts a significant health burden in the region. 2 T2DM accounted for more than 90% of 
diabetes. The International Diabetes Federation (IDF) estimates that between 2011 and 2030 the number of 
people living with diabetes in Africa is expected to double to around 24 million.3 South Africa is not spared 
from the diabetes epidemic, and local studies have shown a high prevalence of diabetes in many communities. A 
cross-sectional study conducted in Bellville South in urban Cape Town, found a high prevalence (28%, 95% CI: 
22.0-30.3) of T2DM amongst adults over 30 years of age.4 
Type 2 diabetes (T2DM) is an independent risk factor for CVD, and conversely CVD is an important cause for 
the decrease in life expectancy of people with diabetes. This has major public health repercussions, which will 
worsen with the projected increased incidence of diabetes. Fox et al5 reviewing data from the Framingham Heart 
Study from a 50-year time period, found that the proportion of CVD attributable to diabetes had increased over 
this time. They also found that, compared to other cardiovascular risk factors such as hypertension, smoking, 
hypercholesterolaemia and obesity, only diabetes showed an increase in the population attributable risk for 
CVD. In addition, diabetics have greater morbidity and mortalities due to CVD compared to non-diabetic 
individuals.  
Other research has found that diabetics have the same high risk of myocardial infarction (MI) as non-diabetics 
with a prior MI.6 This suggests that diabetics should be managed as if they had prior CVD, and that their 
cardiovascular risk factors should be managed as aggressively as non-diabetics with known CVD.  
Globally, the introduction of, and adherence to evidence-based clinical guidelines to change prescribing habits 
have been shown to reduce healthcare costs.7 Evidence-based clinical guidelines should therefore form the basis 
for providing good medical care. However, in practice, obstacles are the approval of guidelines, their 
dissemination, and implementation by clinicians. Internationally, studies reviewing adherence to clinical 
guidelines for the prevention of CVD in diabetics in primary care public settings have found wide ranging levels 
of adherence: from 20% in an Italian study, 8 to 90% in a Scottish study.9  
In South Africa, The Society for Endocrinology, Metabolism and Diabetes of South Africa10 (SEMDSA) 
provides freely available, accepted clinical guidelines for the management of T2DM. They are based on 
consensus, and involved South African experts on diabetes and representatives from stakeholders including the 
Department of Health, and were formulated to be relevant to primary care.10 They recommend that, based on 
their increased cardiovascular risk, type 2 diabetics should receive certain medications: 1) All diabetics should 
receive a statin, regardless of their cholesterol level, 2) Hypertensive diabetics should receive an angiotensin 
converting enzyme inhibitor (ACEI) as first-line anti-hypertensive therapy and 3) Low dose aspirin should be 
prescribed for diabetics as primary prevention for those with known IHD, and as secondary prevention for those 
with additional cardiovascular risk factors. These guidelines, although being best practice, were however, not 
officially released for use in the public sector.  
Primary care plays an important role in the prevention of cardiovascular disease in high risk patients such as 
diabetics.  Most diabetics in South Africa are managed through public sector health services, and in Cape Town 
these are administered by the Metro District Health Services (MDHS) through community health centres 
(CHCs). Patients are attended to by doctors and clinical nurse practitioners (CNPs).  
Generally, the CHCs have been perceived to deliver a substandard level of care for chronic illnesses. A 1999 
study that reviewed diabetic and hypertensive control at primary care services in Cape Town11   showed that, 
despite the prior dissemination of disease management guidelines at CHCs, there was still ongoing poor control 
of chronic diseases at primary care level. The study revealed suboptimal levels of hypertension and diabetes 
control. Two thirds of patients had uncontrolled blood pressure and more than half of diabetics had raised 
glucose levels. There was poor control of risk factors, with most patients having hypercholesterolaemia and high 
levels of smoking. Record keeping was also poor, with documentation of prescribing decisions frequently 
absent. A study performed almost ten years later,12 looking at the management of hypertension at CHCs in Cape 
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Town, showed that deficiencies in the quality of care of chronic conditions at primary care level persisted. Poor 
adherence to clinical guidelines by clinicians was identified as one of the factors leading to poor blood pressure 
(BP) control.  
A 2008 audit, based on the SEMDSA guidelines, reviewed quality of care at 15 MDHS CHCs,13 found 
significant shortcomings in the level of care provided. Among the findings were that patients were poorly 
controlled, staff lacked skills in screening for diabetes complications, and staff struggled with the workload. The 
causes were multifactorial, and recommendations included a structured and systematic approach to care.  
A subsequent Cape Town clinical audit, published in 2012, investigated whether previous audits (performed in 
2005, 2007, 2008 and 2009) resulted in statistically significant improvements in diabetes management at 
CHCs.14 The study findings revealed an improved performance in most clinical processes in diabetes 
management. The application of clinical audits was found to have resulted in quality improvement in the 
management of diabetes in these resource-limited settings. 
 
Aims and Objectives  
This study aimed to determine adherence of Cape Town primary care clinicians to recommended clinical 
guidelines for the prevention of cardiovascular disease in type 2 diabetics.  
The objectives were firstly to determine the demographic characteristics and risk profile for CVD of type 2 
diabetic patients attending the CHC, and secondly to determine the proportions of diabetic patients at a primary 
care level who were being treated according to recommended guidelines to reduce cardiovascular risk: lipid 
treatment – prescription of a statin for all diabetics; appropriate blood pressure treatment –  ACEI as first line 
treatment in the hypertensive diabetic or the accepted alternative if contraindications existed; antithrombotic 
treatment – secondary prevention for diabetics with a history of CVD, or as primary prevention in those with 
risk factors. CHCs were also compared regarding level of adherence to the guidelines. This would show if there 
was any significant difference in prescribing practices between the CHCs.    
                        
Methods  
This cross-sectional study was performed in 2013 and all data collection was performed by the author. One 
hundred folders from each of the three facilities were sampled to power the study with a 95% confidence level 
and precision of 10% for an unknown proportion of adherence overall. Systematic sampling of all T2DM folders 
of patients fulfilling the eligibility criteria was conducted. Reception staff collected folders of patients who are 
known to attend the diabetes “club” on 3 separate days, and every third folder was chosen, and marked. 
Inclusion criteria were: type 2 diabetics of age 40 years or older, being a documented chronic disease clinic 
attendee with at least three visits during the previous year for diabetes, signalling a person with established 
disease in care.  
Data from the clinical notes, as well as the structured clinical record (SCR), 14 a standard tool used for all 
“chronic” or “club” patients, were captured. The SCR contains information about patients’ demographic data 
and cardiovascular risk factors: hypertension, history of IHD (ischaemic heart disease), smoking, family history 
of IHD, BMI (body mass index) and total cholesterol level). Measurements, such as blood pressure and blood 
sugar, from each chronic visit are recorded on this sheet. Clinical information, medication and medical history, 
e.g. cardiovascular risk factors were obtained from the clinician notes in the folder.  
Adherence to SEMDSA guidelines was measured by the appropriate use of an ACEI in hypertensives, lipid-
lowering medication for all diabetics, and aspirin for those diabetics with risk factors. In cases where adherence 
was not met, evidence of the prescriber providing a justification was searched for by folder review. If a reason 
was documented, then the non-adherence was classified as “justified non-adherence”. Not all criteria were 
relevant for all patients: some diabetics were not hypertensive, and were not included in the ACEI calculation; 
patients not on aspirin, with no cardiovascular risk factors, were categorized as “not applicable”. Data regarding 
prior intolerance to specific drugs was also extracted.  
Ethics approval (HREC REF 191/2013) for the study was obtained from the UCT Health Research Ethics 
Committee. Permission to conduct the study at the facilities was obtained from the MDHS and the relevant 
facility managers, and no personal identifiers were recorded.  
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Data analysis  
Data were entered into an Excel spreadsheet. Statistical analysis was performed using the statistical software, 
SAS. Data analysis was descriptive, and results are presented as frequencies and percentages for categorical 
variables, and mean and standard deviation (SD) for continuous variables. Fisher’s exact test, ANOVA or chi-
square tests were used where appropriate to compare the CHCs. Results were considered significant at p<0.05. 
Results  
Three hundred patient folders, 100 from each of three facilities were reviewed. Data pertaining to demographic 
variables was missing in folders from all three facilities. Patient demographic details are given in Table 1. 
Overall, the mean age of patients was 60.4 ± 11.2 years, and most (71.7%) were female. From clinical notes, the 
vast majority – 91% – were classified as hypertensive. For many, cardiovascular risk factors were poorly 
controlled, with mean BMI’s in the obese range (31.3 [SD 5.7] kg/m2, n=200) and the mean total cholesterol 
was 5.5 mmol/l (SD 1.4). As is shown in Table 1, data was incomplete in folders for several cardiovascular risk 
factors, such as BMI, smoking status, family history of CVD, total serum cholesterol and existing IHD. 
Patient data was compared by health centre to determine if there were differences by patient demographic or 
disease profile. The three facilities had equivalent proportions of patients by age, gender, smoking, hypertensive 
status and dyslipidaemia. Significant differences by facility, however, existed for known IHD, family history of 
CVD, and BMI (p<0.05). CHC1 only had 6 patients documented with a history of IHD, whereas CHC2 and 
CHC3 had 15 and 21 respectively. Information about family histories of IHD was largely absent, with CHC3 
faring best with 20% compared to one each for the other two CHCs. BMI recording was poor for all three 
CHCs, with 101 patients having no documented BMI calculation. The difference in documentation between the 
three CHCs was significant, and only half of folders reviewed at CHC3 had a recorded BMI. The mean BMI at 
CHC2 was 29.5 (overweight), while the mean BMI’s at the other two CHCs fell in the obese category (>30) 
(p=0.0012).   
Table 1. Patient Demographics and risk factors for complications of T2DM 
*258 patients there was no indication of the IHD status.
**57 patients there was no indication of smoking status.
***278 patients this data was absent.
^101 patients there was no recorded BMI.
^^26 patients had no total cholesterol result in the folder.
Characteristic All Patients 
(n=300) 
Community Health Centre p-value
CHC 1 (n=100) CHC 2 (n=100) CHC 3 (n=100) 
Age (years), Mean (SD) 60.4 (11.2) 59.7 (12.1) 60.8 (10.7) 60.6 (10.9) p=0.7733 
Gender 
Female (%) 215 (71.7%) 75 (75%) 69 (69%) 71 (71%) p=0.6675 
Hypertension 273 (91%) 88 (88%) 93 (93%) 92 (92%) p=0.4254 
Known IHD 42 (14%)* 6 (6%) 15 (15%) 21 (21%) p=0.0062 
Smoker 74/243** 26/76 24/85 24/82 p=0.4931 
Family history of CVD 19/22*** 1/1 1/1 17/20 p<0.0001 
BMI 
n 199^ 88 62 49 
Mean (SD) 31.3 (5.7) 31.3 (4.9) 29.5 (5.4) 33.4 (6.7) p=0.0012 
Dyslipidaemia 
n 274^^ 94 87 93 




Adherence to guidelines 
Table 2 shows the levels of adherence to the SEMDSA guidelines overall. The results for the individual CHCs 
are shown and compared to each other. Appropriate prescription of antihypertensive medication overall was 201 
(73.6%). This figure includes the 194 (71.1%) with appropriate prescription of an ACEI as well as those 7 
patients who had ACEI-intolerance who were prescribed an ARB. Of the seventy-nine hypertensive patients 
who were not prescribed an ACEI, only 31 (39.2%) had a documented reason for not getting an ACEI. For the 
31 patients with intolerance to the drug, only 7 (22.6%) received the recommended alternative, i.e. an ARB. 
Four (of the 24 who did not receive an ARB) patients were reported to have an ACEI allergy.   
Adherence to the use of a statin was 74.3% overall. None of the 77 patients who were not receiving a statin had 
a documented reason for this. Adherence to the prescription of aspirin in those with increased cardiovascular 
risk was 69.3%. For the 92 patients not receiving aspirin, 18 (19.6%) did not require it, and only 13 (14.1%) had 
a documented reason for its absence.   
There was no significant difference between the CHCs for prescription of ACEI for hypertensives, and use of 
aspirin in patients with risk factors.  There was also no difference between clinics in patient profiles precluding 
aspirin prescription (p=0.3208).  There were however differences between the CHCs for the proportion of 
patients not requiring aspirin . CHC1 had 18 patients with no documented risk factors for CVD, and hence did 
not require aspirin, while both the other CHCs had none. Prescription of statins differed between facilities and 
ranged from 84% (CHC1) to 68% (CHC2) (p<0.05). 




95% CI            Community Health Centre p-value 







1. ACEI       
Use of ACEI in HTN 194 
(71.1%) 
64.6 -77.4 59 (67%) 62 (66.7%) 73 (79.3%) p=0.0985 
Justified non-adherence 31 (39.2%)  11 (38%) 12 (38.7%) 8 (42.1%) p=0.9560 
ACEI-intolerance (n=31) +ARB 
prescribed 
7 (22.6%)  2 (18.2%) 3 (25%) 2 (25%) P=0.5285 
ACEI/ARB allergy    0 (0%) 2 (16.7%) 2 (25%)  
       
2. Statin       




68.2-79.8 84 (84%) 68 (68%) 71 (71%) p=0.0200 
Justified non-adherence  0/77  0  0  0  
       
3. Aspirin       
Use of aspirin if risk factors 208 
(69.3%) 
62.7-75.0 70 (70%) 69 (69%) 69 (69%) p=1.000 
Justified non-adherence 13 (14.1%)  3 (10%) 7 (22.6%) 3 (9.7%) p=0.3208 
Not applicable (no risk) 18  18 (60%) 0 (0%) 0 (0%) p<0.0001 
 
Discussion 
Diabetes accounts for a significant health and economic burden locally and worldwide, and the predictions are 
that the global prevalence of diabetes will increase.1-4 Research has shown T2DM to be an important 
contributing risk factor for CVD,5 and CVD is as a leading cause of mortality in diabetic patients. 6 The 
management of diabetes must therefore cover not only blood sugar control, but also address the reduction of risk 
factors for cardiovascular disease.  
The SEMDSA has published guidelines for the management of T2DM.10 These guidelines provide 
recommendations for blood pressure and lipid treatment, and for the use of aspirin. The guidelines are freely 
available, but it is not known how widely they are disseminated to facilities managing diabetics, or if their 
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implementation by clinicians is monitored. Studies performed elsewhere8,9 have reported varying levels of 
adherence to guidelines. This study aimed to determine if type 2 diabetic patients attending primary care clinics 
were prescribed treatment, as recommended by SEMDSA guidelines, to reduce their cardiovascular risk.  
This study revealed deficiencies in both adherences to disease management guidelines and documentation of 
individual patient management. Cardiovascular risk reduction was poor. The results showed obesity to be a 
major problem (mean BMI 31.3 ± 5). There were moderate levels of adherence to clinical guidelines, developed 
to reduce cardiovascular risk in diabetics. Appropriate use of ACEI in hypertension and use of statins was 71% 
and 74% respectively, with appropriate aspirin use at 69% overall.  
Reasons for observed differences between facilities in prescribing patterns, such as statins, are unknown and 
require further investigation. It may be due to clinician ignorance about latest guidelines for diabetic 
management. Continued medical education may be unevenly implemented at the various facilities, and this 
merits attention. 
In-service updates about the latest evidence-based clinical guidelines should promote the use of guidelines 
amongst clinicians, and needs to be scheduled into the working routine in the services. In this study updates and 
training would have increased clinicians’ knowledge about the importance of identifying cardiovascular risk 
factors in diabetic patients and its appropriate management. A study at a South African district hospital’s 
diabetic clinic showed that the quality of care, as well as diabetic control, improved after the introduction of a 
physician education programme. 15 
Documentation across all facilities was poor for both the structured clinical record (the chronic patient form to 
record investigations and cardiovascular risk) and the clinical notes which contain prescribing decisions. The 
results obtained from this study compared well with international studies reviewing clinician adherence to 
therapeutic guidelines for diabetic patients. In different settings levels of adherence varied widely, ranging from 
20% in an Italian study,8 to 90% in a Scottish study.9 Nonetheless, they also show that in our setting there is still 
room for improvement. 
Limitations 
This study audited one aspect of assessing adherence to clinical guidelines, i.e. pharmacological therapy. It did 
not explore the facilitators or barriers to good adherence. These factors may include clinicians’ inadequate 
knowledge of appropriate therapy; high turnovers of medical staff at the CHCs; inadequate orientation of new 
clinical staff to expected practice; poor availability of clinical guidelines; and the presence/absence of regular in-
service education session. In addition, the presence of health promotion messaging in clinical notes, in the 
facility and dedicated health promotion staff was not collected. 
Poor or insufficient documentation contributed to a potential misclassification bias as the researcher classified 
absent information as non-adherence to guidelines, and this would result in an underestimation of performance. 
The facility differences observed may be the result of the different clinician categories prescribing practices - 
doctors or CNPs. The study was not powered to compare different categories of clinicians, i.e. doctors vs 
clinical nurse practitioners. It is difficult to identify the clinician category from clinical notes and this would 
have affected the sampling strategy.  
Conclusion and recommendations 
The study points to areas for improvement in the management of diabetes at primary care level. Prevention of 
cardiovascular disease and risk factor reduction should be an important goal in the management of the diabetic 
patient, but cardiovascular risk factors were found to be poorly controlled. Higher levels of adherence to 
recommended clinical guidelines by clinicians are essential for improving quality of care. This can be aided by 
the facilities improving awareness and availability of these guidelines. Good clinical notes, which includes 
documenting the rationale for prescribing decisions, improves continuity and quality of care. This would 
contribute to reducing costs arising from the consequences of inadequate management. 
 Continued medical education at the CHCs would help to keep clinicians informed of current evidence-based 
guidelines, and increase the rates of guideline implementation. Processes, such as audit cycles, with feedback to 
clinicians, would be helpful to monitor and identify areas for improvement in primary care prescribing. In 
addition, a stronger focus on non-pharmacological health promotion messaging around obesity is critical.  
Consideration of the use of other metrics for obesity that are stronger predictors of cardio-vascular risk such as 
waist circumference (WC) 16 are needed. While BMI is an important predictor of health risk, WC predicts both 
abdominal and non-abdominal fat. This is currently not included in the SEMDSA. BMI is widely used in 
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primary settings as a tool to measure for obesity, yet WC is simpler to measure. This suggests that it would be 
more appropriate for the CHCs to replace BMI with WC on the structured clinical record.  
A revised primary care oriented guideline with useful tools for in-service training that uses a bio-psycho-social 
approach, if implemented, would assist improving the care of T2D. This guideline would incorporate a focus on 
both clinical skills, management guidelines, including appropriate health promotion messages.  The tools should 
include revised stationery, e.g. a modified structured clinical record which includes SEMDSA medication 
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Data capture sheet continued: 
Name of 
CHC 












Patient Demographics and risk factors for complications of T2DM 
Adherence to SEMDSA guidelines 
Characteristic All Patients 95% CI  Community Health Centre p-value
CHC 1 CHC 2 CHC 3 
1. ACEI
Use of ACEI in HTN 
Justified non-adherence 
ACEI-intolerance +ARB prescribed 
ACEI/ARB allergy 
2. Statin
Use of statin in primary prevention 
Justified non-adherence  
3. Aspirin
Use of aspirin if risk factors 
Justified non-adherence 
Not applicable (no risk) 
Characteristic All Patients 
(n=300) 
Community Health Centre p-value













Total cholesterol (mmol/l) 
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